Equities Research Analysts’ Updated EPS Estimates for November, 15th (AKBA, APHB, APTO, CARG, CLVS, CRME, EYEG, FENR, HD, MLSS)

Equities Research Analysts’ updated eps estimates for Wednesday, November 15th:

Akebia Therapeutics (NASDAQ:AKBA) had its buy rating reissued by analysts at . The firm currently has a $24.00 target price on the stock.

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) had its buy rating reissued by analysts at . They currently have a $5.00 target price on the stock.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its buy rating reiterated by analysts at . The firm currently has a $4.00 target price on the stock.

CarGurus (NASDAQ:CARG) had its sector perform rating reissued by analysts at Royal Bank Of Canada. They currently have a $34.00 target price on the stock, up from their previous target price of $33.00.

Clovis Oncology (NASDAQ:CLVS) had its outperform rating reiterated by analysts at . currently has a $90.00 target price on the stock, down from their previous target price of $107.00.

Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) had its positive rating reaffirmed by analysts at . The firm currently has a $5.00 target price on the stock, down from their previous target price of $8.00.

Eyegate Pharmaceuticals (NASDAQ:EYEG) had its buy rating reissued by analysts at .

Fenner PLC (LON:FENR) had its buy rating reaffirmed by analysts at . They currently have a GBX 425 ($5.59) target price on the stock.

Home Depot, Inc. (The) (NYSE:HD) had its buy rating reiterated by analysts at UBS AG. UBS AG currently has a $186.00 target price on the stock, up from their previous target price of $175.00.

Milestone Scientific (NYSEAMERICAN:MLSS) had its buy rating reiterated by analysts at . currently has a $4.00 target price on the stock. The analysts wrote, “3Q17 revenue of $2.85M, down 10.4% y/y, was slightly above our estimate of $2.74M.””

NCS Multistage Holdings (NASDAQ:NCSM) had its outperform rating reissued by analysts at Wells Fargo & Company. They currently have a $30.00 price target on the stock, down from their previous price target of $35.00.

Philip Morris International (NYSE:PM) had its outperform rating reaffirmed by analysts at Wells Fargo & Company. They currently have a $135.00 price target on the stock, down from their previous price target of $140.00.

Quest Resource Holding Corporation. (NASDAQ:QRHC) had its buy rating reaffirmed by analysts at . They currently have a $5.00 target price on the stock.

Strongbridge Biopharma PLC (NASDAQ:SBBP) had its buy rating reaffirmed by analysts at .

SITO Mobile (NASDAQ:SITO) had its outperform rating reaffirmed by analysts at .

Splunk (NASDAQ:SPLK) had its overweight rating reiterated by analysts at Piper Jaffray Companies. They currently have a $80.00 target price on the stock.

Receive News & Ratings for Akebia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply